Lion's Mane (Hericium erinaceus) — Evidence for Neurodegeneration

Lion's Mane (Hericium erinaceus) — Evidence for Neurodegeneration

Overview

Lion's Mane (Hericium erinaceus) — Evidence for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Lion's Mane (Hericium erinaceus) — Evidence for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Improving effects of Hericium erinaceus on mild cognitive impairment: a double-blind placebo-controlled clinical trial</td>
</tr>
<tr>
<td class="label">PMID</td>
<td>[18844328](https://pubmed.ncbi.nlm.nih.gov/18844328/)</td>
</tr>
<tr>
<td class="label">Design</td>
<td>Double-blind, parallel-group, placebo-controlled RCT</td>
</tr>
<tr>
<td class="label">Sample</td>
<td>30 participants with mild cognitive impairment (15 per group)</td>
</tr>
<tr>
<td class="label">Dosage</td>
<td>4 × 250 mg tablets of 96% lion's mane dry powder, 3× daily (total 3 g/day)</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>16 weeks active + 4 weeks off-treatment observation</td>
</tr>
<tr>
<td class="label">Outcome</td>
<td>Revised Hasegawa Dementia Scale (HDS-R)</td>
</tr>
<tr>
<td class="label">Results</td>
<td>Significant improvement in HDS-R scores at weeks 8, 12, and 16 vs. placebo; scores declined 4 weeks after discontinuation</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Improvement of cognitive functions by oral intake of Hericium erinaceus</td>
</tr>
<tr>
<td class="label">PMID</td>
<td>[31413233](https://pubmed.ncbi.nlm.nih.gov/31413233/)</td>
</tr>
<tr>
<td class="label">Design</td>
<td>Randomized, double-blind, placebo-controlled</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>12 weeks</td>
</tr>
<tr>
<td class="label">Dosage</td>
<td>Fruiting body extract (specific dose not reported in abstract)</td>
</tr>
<tr>
<td class="label">Outcome</td>
<td>Mini-Mental State Examination (MMSE), Benton visual retention test, Standard verbal paired-associate learning test</td>
</tr>
<tr>
<td class="label">Results</td>
<td>Significant improvement in MMSE scores; prevented cognitive deterioration</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia</td>
</tr>
<tr>
<td class="label">PMID</td>
<td>[32581767](https://pubmed.ncbi.nlm.nih.gov/32581767/)</td>
</tr>
<tr>
<td class="label">Design</td>
<td>Double-blind, placebo-controlled, randomized parallel-group</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>49 weeks</td>
</tr>
<tr>
<td class="label">Dosage</td>
<td>Three 350 mg capsules/day of erinacine A-enriched mycelia (5 mg/g erinacine A)</td>
</tr>
<tr>
<td class="label">Outcome</td>
<td>CASI, MMSE, IADL, biomarkers, neuroimaging</td>
</tr>
<tr>
<td class="label">Results</td>
<td>Significant MMSE improvement vs. placebo; better IADL scores; enhanced contrast sensitivity; only 4 dropouts due to mild adverse events (abdominal discomfort, nausea, skin rash)</td>
</tr>
<tr>
<td class="label">Study</td>
<td>The Acute and Chronic Effects of Lion's Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults</td>
</tr>
<tr>
<td class="label">PMID</td>
<td>[38004235](https://pubmed.ncbi.nlm.nih.gov/38004235/)</td>
</tr>
<tr>
<td class="label">Design</td>
<td>Double-blind, parallel groups, pilot study</td>
</tr>
<tr>
<td class="label">Sample</td>
<td>Young adults</td>
</tr>
<tr>
<td class="label">Results</td>
<td>Shows promise for improving cognitive function and mood</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Source</td>
</tr>
<tr>
<td class="label">Fruiting body</td>
<td>Mushroom caps</td>
</tr>
<tr>
<td class="label">Mycelium</td>
<td>Cultured mycelium</td>
</tr>
<tr>
<td class="label">Mycelium on grain</td>
<td>Commercial supplements</td>
</tr>
<tr>
<td class="label">Brand</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Host Defense</td>
<td>Mycelium extract</td>
</tr>
<tr>
<td class="label">Nootropics Depot</td>
<td>Dual extract</td>
</tr>
<tr>
<td class="label">Real Mushrooms</td>
<td>Fruiting body</td>
</tr>
<tr>
<td class="label">Criterion</td>
<td>Rating</td>
</tr>
<tr>
<td class="label">Mechanism plausibility</td>
<td>High (NGF stimulation documented)</td>
</tr>
<tr>
<td class="label">Clinical evidence strength</td>
<td>Moderate (small RCTs, mostly MCI)</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>Excellent</td>
</tr>
<tr>
<td class="label">Relevance to CBS/PSP</td>
<td>Speculative but safe to try</td>
</tr>
<tr>
<td class="label">Overall</td>
<td>Consider — low-risk supportive therapy</td>
</tr>
</table>

Lion's mane (Hericium erinaceus) is an edible mushroom traditionally used in East Asian medicine that has gained attention for its potential neurocognitive benefits. The fungus contains two classes of bioactive compounds—hericenes (from the fruiting body) and erinacines (from the mycelium)—that stimulate nerve growth factor (NGF) synthesis in astrocytes.

Mechanism of Action

Primary Mechanism: NGF Stimulation

The primary therapeutic mechanism of lion's mane involves stimulation of [nerve growth factor (NGF)](/proteins/nerve-growth-factor) synthesis. The bioactive compounds work through the following pathway:

The stimulation of NGF supports:

• Cholinergic neuron survival in the basal forebrain
• Hippocampal neurogenesis
• Synaptic plasticity and dendritic branching
• Myelin maintenance

Secondary Effects

Some studies show downstream [BDNF](/proteins/bdnf-protein) upregulation, but this appears to be secondary to NGF signaling rather than a direct effect[@mori2009]. The evidence for direct BDNF stimulation is weaker than for NGF.

Blood-Brain Barrier Penetration

Erinacines (particularly erinacine A) have demonstrated ability to cross the blood-brain barrier in animal models[@chong2019], which is critical for CNS therapeutic efficacy.

Clinical Evidence

Mori et al. (2009) — Mild Cognitive Impairment RCT

This study provides the most direct evidence for cognitive benefits in MCI, though the sample size is small (n=30)[@saitsu2019].

Saitsu et al. (2019) — Healthy Adults RCT

This study extends the evidence to healthy adults with age-related cognitive decline[@li2020].

Li et al. (2020) — Early Alzheimer's Disease Pilot

This study specifically used erinacine A-enriched mycelium, addressing the formulation issue discussed below[@docherty2023].

Docherty et al. (2023) — Young Adults Pilot

Formulations: Critical Distinction

Fruiting Body vs. Mycelium

The bioactive compound profile differs dramatically between parts:

Critical issue: Many commercial "lion's mane" supplements are mycelium grown on grain, which contains negligible erinacines. The fruiting body contains hericenones but not erinacines. True dual extracts or dedicated mycelium products are required for maximal NGF-stimulating activity.

Recommended Products

Dosage

• Fruiting body extract (hericenes only): 1,000–3,000 mg/day
• Mycelium extract (erinacines): 500–1,000 mg/day
• Dual extract: 1,000–2,000 mg/day

Relevance to Atypical Parkinsonism (CBS/PSP)

Potential Benefits

• Cholinergic support: NGF promotes cholinergic neuron survival, potentially helping with cognitive symptoms in [corticobasal syndrome](/diseases/corticobasal-syndrome) and [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy)
• Cognitive function: The RCT evidence supports improvement in MCI and age-related cognitive decline
• Safety profile: Excellent safety—very few adverse events reported in clinical trials

Limitations

• No direct tau pathology evidence: No studies specifically examining effects on 4R-tauopathy
• Limited neurodegenerative disease data: Most studies in MCI or healthy adults, not in established PD or atypical parkinsonism
• Mechanistic gap: While NGF stimulation is well-documented in vitro, the translation to meaningful clinical benefit in tauopathies remains speculative

Assessment

Safety Profile

Lion's mane demonstrates an excellent safety profile across clinical trials:

• Adverse events: Rare; mild GI discomfort, nausea, skin rash in some users[@docherty2023]
• Drug interactions: None well-documented
• Contraindications: None established
• Long-term data: Limited beyond 49 weeks in one trial

Related Pages

• [Personalized Treatment Plan — Atypical Parkinsonism — Lion's Mane section](/proteins/parkin)
• BDNF Therapy — Related neurotrophic approaches
• [Nerve Growth Factor (NGF) — Target protein](/proteins/nerve-growth-factor)
• PI3K/Akt/mTOR Signaling — Downstream neurotrophic pathway

References